Clinical Trial

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 31, 2026 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2023-02-24; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT05757219
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Incyte Corporation
Conditions Diffuse Large B Cell Lymphoma
Enrollment 27 participants
Start Date 2023-05-19
Primary Completion 2026-06-20 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-31